source
- FDA approves Lilly's new combination therapy for advanced breast cancerThe U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer. The therapy pairs two agen…
- Telix to acquire ITM Isotope for $1.65 billion, targeting radioligand therapy marketTelix Pharmaceuticals announced it will acquire ITM Isotope Technologies Munich for $1.65 billion upfront, securing a radiopharmaceutical supply network. The acquisition brings an R&D pipeline cen…